Enaltus Completes Add-on Acquisition

Enaltus has acquired the assets of Mitchell-Vance Laboratories. Enaltus is a portfolio company of HealthEdge Investment Fund, a Tampa, Florida-based private equity fund focused exclusively on healthcare.

PRESS RELEASE

Enaltus, LLC (“Enaltus”) recently acquired the assets of Mitchell-Vance Laboratories, d/b/a ScarAway® (“ScarAway” or the “Company”). Enaltus is a portfolio company of HealthEdge Investment Fund, L.P. (“HealthEdge”), a Tampa, Florida-based private equity fund focused exclusively on healthcare.
Founded in 2008 in Guilford, Connecticut, ScarAway is a line of OTC, professional grade, topical silicone scar treatments sold nation-wide through more than 20,000 retail stores. The ScarAway brand is an FDA-regulated medical device that utilizes clinically proven silicone technology and innovative treatment modalities to help flatten, soften, smooth, fade or improve the size and appearance of scars, particularly keloid and hypertrophic (raised) scars resulting from surgery, injuries, burns, or acne. The ScarAway line consists of seven SKUs which can be used on any part of the body including the face, ears, neck, scalp, arms, hands, and joint areas.
Enaltus is a Suwannee, Georgia-based business with U.S. and international presence that is primarily focused on developing, marketing, and selling skincare products to physicians and direct to consumers via national and independent retailers. The Company’s flagship products, Kelo-cote® and bioCorneum®, are patented, self-drying, silicone gels, and sprays used for scar treatment and prevention.
“Enaltus has become a leading provider in the professional and retail scar management category across the U.S. and a significant player in the specialty skincare market through strong organic growth of its core brands, licensing of new brands, and strategic acquisitions, including Belli Skincare, a leader in skincare solutions for pre and post natal women and infants, MedAltus, a provider of complete e-commerce skin store solutions for physicians, and now ScarAway,” commented Jeff Thompson, Enaltus CEO and HealthEdge Partner.
Jessica Rowen, President of Mitchell-Vance Laboratories added, “We are excited about the acquisition of ScarAway by Enaltus and believe the combined portfolio of brands will gain additional distribution and benefit from similar, but different, experiences in the scar management category. The combination of the ScarAway and Kelo-cote brands will enhance our capability to provide customers with best in class professional-grade scar treatment solutions.”